<DOC>
	<DOCNO>NCT03100825</DOCNO>
	<brief_summary>The purpose study provide long term safety data QVM149 Japanese patient asthma registration QVM149 Japan .</brief_summary>
	<brief_title>A Long-term Safety Study QVM149 Japanese Patients With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Written informed consent must obtain assessment perform . Male female adult patient ≥ 18 year old . Patients diagnosis persistent asthma ( GINA 2016 ) period least 1 year prior Visit 1 . Patients used medium high dose ICS/LABA combination asthma least 6 month stable dose regimen least 4 week prior Visit 1 . An ACQ7 score ≥ 1.5 Visits 2 . Prebronchodilator FEV1 ≥ 40 % ≤ 85 % predict normal value patient withhold bronchodilator Visit 2 . Patients must demonstrate reversibility define increase FEV1 ≥ 12 % 200 mL within 30 minute administration 400 µg salbutamol Visit 2 . Patients asthma attack/exacerbation require systemic steroid hospitalization emergency room visit within 6weeks Visit 1 . Patients ever require intubation severe asthma attack/exacerbation . Patients clinical condition likely worsen ICS administration ( e.g . glaucoma , cataract fragility fracture ) accord investigator 's medical judgment risk participate study . Patients narrowangle glaucoma , symptomatic benign prostatic hyperplasia ( BPH ) bladderneck obstruction severe renal impairment urinary retention . BPH patient stable treatment consider . Patients respiratory tract infection asthma worsen determined investigator within 4 week prior Visit 1 Visit 1 Visit 99 . Patients may rescreened 4 week recovery respiratory tract infection asthma worsen . Patients history chronic lung disease asthma , include ( limited ) COPD , sarcoidosis , interstitial lung disease , cystic fibrosis , clinically significant bronchiectasis active tuberculosis . Patients severe narcolepsy and/or insomnia Pregnant nursing ( lactate ) woman Women childbearing potential unless use highly effective method contraception dose 30 day stop investigational medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>QVM149 ,</keyword>
	<keyword>Asthma ,</keyword>
	<keyword>Japanese ,</keyword>
	<keyword>Allergic asthma ,</keyword>
	<keyword>Allergy trigger asthma ,</keyword>
	<keyword>Reactive asthma ,</keyword>
	<keyword>Asthma attack ,</keyword>
	<keyword>Difficulty breathe</keyword>
</DOC>